The FDA has approved a new biosimilar of Roche’s breast cancer drug Herceptin, from Samsung Bioepis and Merck & Co, ahead of the original drug’s US patent expiry in June.

The EMA’s human medicines committee has recommended approval of a fixed-dose combination of Roche’s breast cancer drugs Herceptin and Perjeta – part of the company’s defense against ...

Other protein-based medicines include GLP-1 weight-loss drugs like Ozempic and Wegovy, and antibody treatments like Herceptin for cancer. How can AI develop new medicines like these? If you design ...

This article provides an update on developments in the biosimilar space in Canada—regulatory, approvals, pending submissions, litigation, and market ...

Herceptin has benefited about three million people since that time, dramatically increasing the 10-year survival rate—and the cancer-free rate—for what was once one of the worst medical diagnoses.